Illumina, Inc. (ILMN): Price and Financial Metrics

Illumina, Inc. (ILMN)

Today's Latest Price: $305.50 USD

0.04 (0.01%)

Updated Sep 29 4:00pm

Add ILMN to Watchlist
Sign Up

Overall POWR Rating

POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank

Industry Rank:

Ranked of 376 in Biotech

See all "A" rated Strong Buy stocks

ILMN Stock Summary

  • Illumina Inc's market capitalization of $44,597,160,000 is ahead of 95.65% of US-listed equities.
  • The price/operating cash flow metric for Illumina Inc is higher than 90.12% of stocks in our set with a positive cash flow.
  • ILMN's price/sales ratio is 13.31; that's higher than the P/S ratio of 89.42% of US stocks.
  • Stocks with similar financial metrics, market capitalization, and price volatility to Illumina Inc are NTES, ADI, SPOT, DXCM, and BIIB.
  • Visit ILMN's SEC page to see the company's official filings. To visit the company's web site, go to
ILMN Daily Price Range
ILMN 52-Week Price Range

ILMN Stock Price Chart Technical Analysis Charts

ILMN Price/Volume Stats

Current price $305.50 52-week high $404.20
Prev. close $305.46 52-week low $196.78
Day low $302.37 Volume 1,611,186
Day high $309.70 Avg. volume 1,284,918
50-day MA $349.38 Dividend yield N/A
200-day MA $324.86 Market Cap 44.60B

Illumina, Inc. (ILMN) Company Bio

Illumina is a global leader in DNA sequencing and array-based technologies, serving customers in the research, clinical and applied markets. The company's products are used for applications in the life sciences, oncology, reproductive health, agriculture and other emerging segments. The company was founded in 1998 and is based in San Diego, California.

ILMN Price Forecast Based on DCF Valuation

Current PriceDCF Fair Value Target: Forecasted Gain:
$305.50$153.34 -50%

The table below illustrates the output of a discounted cash flow forecast using a variety of scenarios for Illumina Inc. To summarize, we found that Illumina Inc ranked in the 29th percentile in terms of potential gain offered. We should note, though, that the most conservative analysis suggests this stock will yield negative results -- and thus may be a potential short opportunity. In terms of the factors that were most noteworthy in this DCF analysis for ILMN, they are:

  • Interest coverage, a measure of earnings relative to interest payments, is 21.05; that's higher than 86.13% of US stocks in the Healthcare sector that have positive free cash flow.
  • The business' balance sheet suggests that 4% of the company's capital is sourced from debt; this is greater than just 12.29% of the free cash flow producing stocks we're observing.
  • ILMN's estimated cost of debt, based largely on its market capitalization and its interest coverage ratio, is 2%; for context, that number is higher than 46.05% of tickers in our DCF set.

Terminal Growth Rate in Free Cash FlowReturn Relative to Current Share Price

For other companies in the Healthcare that have a similar discounted cashflow valuation profile (and ensuing price forecasts) as ILMN, try LMAT, GILD, HAPP, ZTS, and CPIX.

ILMN Latest News Stream

Event/Time News Detail
Loading, please wait...

ILMN Latest Social Stream

Loading social stream, please wait...

View Full ILMN Social Stream

Latest ILMN News From Around the Web

Below are the latest news stories about Illumina Inc that investors may wish to consider to help them evaluate ILMN as an investment opportunity.

Week In Review: Illumina Pays $8 Billion To Acquire GRAIL, An Early-Stage Cancer Testing Company

Deals and Financings Illumina (ILMN) will acquire GRAIL (GRAL), an Illumina spin-out that is developing an early screening test for multiple forms of cancer, for $8 billion in cash and stock (see story). In 2017, GRAIL bought Cirina, a Hong Kong-San Francisco liquid biopsy company cofounded by Dr. Dennis Lo,...

ChinaBio Today on Seeking Alpha | September 28, 2020

Illumina to Announce Third Quarter 2020 Financial Results on Thursday, October 29, 2020

SAN DIEGO--(BUSINESS WIRE)---- $ILMN #ILMN--Illumina, Inc. (NASDAQ:ILMN) today announced that it will issue results for the third quarter 2020 following the close of market on Thursday, October 29, 2020. On the same day, at 2:00 pm Pacific Time (5:00 pm Eastern Time) Francis deSouza, President and Chief Executive Officer, and Sam Samad, Chief Financial Officer, will host a conference call with analysts, investors, and other interested parties to discuss financial and operating results. Conference Call Details

Business Wire | September 28, 2020

Has the era of liquid biopsies finally arrived? Illumina thinks so

Illumina's (ILMN) $8B takeout of liquid biopsy developer GRAIL, which it formed in 2016 with funding assistance from the likes of Bill Gates and Jeff Bezos, may be a watershed event for its use in cancer detection and management.It is developing a multi-cancer early detection test called Galleri that detects...

Seeking Alpha | September 26, 2020

Illumina and Grail CEOs defend their deal to investors

The CEOs of the two companies told STAT it would take time for investors to understand the advantages of combining the two firms.

STAT News | September 25, 2020

Exact Sciences Jumps as Company Presents at Cowen Event

At the summit Chief Executive Kevin Conroy discussed new early data for the company's multicancer-screening technology, according to a Bloomberg report. "We will bring the best CRC blood test to physicians and patients, though we don't believe the blood test will replace colonoscopy or Cologuard," Conroy said, according to the report. Cowen analyst Doug Schenkel, speaking during the question-and-answer portion of the presentation, called the data "new and exciting."

Yahoo | September 24, 2020

Read More 'ILMN' Stories Here

ILMN Price Returns

1-mo -13.70%
3-mo -17.11%
6-mo 11.91%
1-year 0.42%
3-year 53.36%
5-year 94.33%
YTD -7.91%
2019 10.61%
2018 37.27%
2017 70.64%
2016 -33.30%
2015 3.99%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.7191 seconds.